Report

Analyst Pin-board: DBD – Rising competition requires changes

DBD’s growth is slow in recent years. 2015 is the exception as DBD divested from FKB, and merge between Bidiphar (specialize in distribution) and Bidiphar 1 (specialize in manufacturing). The company has been well-known for its injection drugs and anticancer drugs. 70% of its revenue comes from ETC (hospital) channel.

Provider
Viet Dragon Securities
Viet Dragon Securities

Viet Dragon Securities belongs to top 20 biggest securities companies in terms of chartered capital in Vietnam. With a qualified, dedicated and professional team, a widespread network, advanced technology, diversified products and services, and good relationship with local and foreign institutions, we provide a wide range of services and products to our clients both individuals and institutions, both local and foreign. We commit to provide our clients with promising investment opportunities and a comprehensive and professional financial investment services.

RongViet Research reports are diversified and abundant, along with in-depth analysis and performed by experienced, highly-qualified and knowledgeable teams. With the objectives of transparency, accurate and timely manner, RongViet believes that our products would always be important sources of information for customers/investors’ investment decisions.

Other Reports from Viet Dragon Securities

ResearchPool Subscriptions

Get the most out of your insights

Get in touch